BTI
NTLA icon

Blue Trust Inc’s Intellia Therapeutics NTLA Stock Holding History

Blue Trust Inc’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$173 – 2667
2025
Q3 		$173 Hold
10
– – ﹤0.01% 2518
2025
Q2 		$94 Sell
10
-53
-84% -$435 ﹤0.01% 2406
2025
Q1 		$448 Buy
63
+53
+530% +$535 ﹤0.01% 2368
2024
Q4 		$117 Sell
10
-4,179
-100% -$65.2K ﹤0.01% 2399
2024
Q3 		$93.8K Buy
4,189
+2,707
+183% +$62.4K ﹤0.01% 1254
2024
Q2 		$40.8K Buy
1,482
+1,398
+1,664% +$33.3K ﹤0.01% 1332
2024
Q1 		$2.31K Sell
84
-735
-90% -$20.4K ﹤0.01% 1796
2023
Q4 		$26K Buy
+819
New +$23.5K ﹤0.01% 1188
2023
Q2 		– Sell
-23
Closed -$1K – 2365
2023
Q1 		$1K Sell
23
-88
-79% -$3.45K ﹤0.01% 2183
2022
Q4 		$6K Buy
111
+96
+640% +$4.57K ﹤0.01% 1681
2022
Q3 		$1K Buy
+15
New +$931 ﹤0.01% 1969

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Blue Trust Inc's NTLA Position: Q4 2025 in Review

Blue Trust Inc sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 10 shares — an estimated $173 sold.

Blue Trust Inc first reported a position in NTLA in Q3 2022 and held it in 11 quarters. The position peaked at $93.8K in Q3 2024. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Blue Trust Inc reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Blue Trust Inc sold 10 Intellia Therapeutics shares in Q4 2025, an estimated $173.
  • Blue Trust Inc first reported a position in Intellia Therapeutics in Q3 2022 and held it in 11 quarters.
  • Blue Trust Inc's Intellia Therapeutics position peaked at $93.8K in Q3 2024.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Blue Trust Inc's 13F filing for Q4 2025, filed 16 Jan 2026.